Global Life Science Leader [ ]
BGI’s unparalleled understanding of its clients’ competitive landscape in conjunction with best-in-class executive through board level recruiting makes it the search firm of choice with clients that are truly focused on driving their success and bringing exceptional shareholder value.
CEO Board Executive Learn More
Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value.
Biotechnology Pharmaceutical Medical Device Contract Services Learn More
Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value.
Saving Lives Improving Treatments Learn More Maximizing Shareholder Value Finding Cures Helping Clients

Encompassing all Executive through Board Positions in Life Sciences

Director of the Board

Yes

Chief Executive Officer

Yes

Chief Business Officer

Leading publicly traded biopharmaceutical stem cell company.

No

Chairman of the Board

Yes

Chief Financial Officer

Formerly Aastrom Biosciences

Yes

Chief Operating Officer

Yes

Chief Scientific Officer

Leading publicly traded monoclonal antibody & oncology company

No

Executive Vice President, Orthopedics and Chief Operating Officer

Formerly BioMimetic Therapeutics, Inc.

Yes

In The News

President Donald Trump signed an executive order Monday that calls for reducing the number of required vaccinations for children in a move that backs a revised immunization schedule pushed by the Department of Health and Human Services.

Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have to be dramatic.

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to secure a decisive clinical win to enter the U.S. market.

The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.

Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.

Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of the plant was classified as “Official Action Indicated.”

Piper Sandler Spring Biopharma Symposium
Boston, MA April 15-16

Needham & Co. Annual Healthcare Conference
New York, NY April 13-16

Society of Gynecologic Oncology Annual Meeting (SGO)
San Juan, Puerto Rico April 11-13

American Academy of Dermatology (AAD)
Denver, CO March 27-30

Society of Toxicology Annual Meeting (SOT)
San Diego, CA March 22-26

American Society of Clinical Oncology Genitourinary Cancers Symposium
San Francisco, CA February 26-28

See More Events